• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Patients twice as likely to take anticoagulants with artificial intelligence platform

April 7, 2017 By Sarah Faulkner

Patients twice as likely to take anticoagulants with artificial intelligence platformResearchers from the Stern Stroke Center at Montefiore Medical Center published trial results this week showing that stroke survivors were twice as likely to take anticoagulants when using an artificial intelligence platform compared to patients receiving standard therapies.

The AI platform, AiCure, features software algorithms on smartphones that confirm patient identify, medication and drug ingestion. Patients receive automated reminders and precise dosing instructions and healthcare workers can review data in real-time.

The platform allows for healthcare practitioners to detect nonadherence early and ensure patients stay on track with their regimen, according to the researchers.

“In the absence of routine laboratory monitoring, artificial intelligence has the potential to automate a critical component of care — adherence monitoring — and provide continuity of care between visits to ensure patients persist with their therapy and get full therapeutic benefit,” lead author Dr. Daniel Labovitz said in prepared remarks.

The 12-week study enrolled ischemic stroke survivors and randomly assigned them to either use the AI platform or receive treatment as usual. Researchers measured the concentration of anticoagulants in blood samples to evaluate treatment adherence.

Blood tests revealed that all of the patients in the AI branch took medication regularly, versus 50% of their counterparts in the control arm.

“Many patients are unable to self-manage and are at increased risk of stroke and bleeding,” co-author & AiCure’s chief strategy officer Laura Shafner said. “The use of technology and artificial intelligence has the potential to significantly improve health outcomes and reduce costs in clinical care.”

The researchers also noted that the patients, with an average age of 57 years old, were able to easily learn how to use the smartphone-based technology, despite having little prior experience. This AI platform is the only automated technology to be validated in ambulatory settings against drug concentration levels, according to the team.

The study was supported by a grant from the National Center for Advancing Translational Sciences of the National Institutes of Health.

Filed Under: Big Data, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: AiCure, National Institutes of Health

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS